MedTrace Logo

Induction of Transplant Tolerance in LDLT Via iTS

NCT04950842 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-03-28

No results posted yet for this study

Summary

The purpose of this clinical trial is to examine the immunotolerance-inducing ability (effectiveness) of induced inhibitory T cells JB-101 in patients with living-donor liver transplantation using "whether or not operational tolerance is achieved" as an index.

And the safety of JB-101 will be evaluated.

Conditions

  • Living-donor Liver Transplantation

Interventions

BIOLOGICAL

JB-101

induced T cell with suppressive function

Sponsors & Collaborators

  • Junten Bio Co., Ltd.

    collaborator INDUSTRY

  • Juntendo University

    lead OTHER

Principal Investigators

  • Koichiro Uchida, M.D.,Ph.D. · Juntendo University Advanced Research Institute for Health Science

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2026-02-28
Completion
2026-02-28

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04950842 on ClinicalTrials.gov